Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ibrutinib plus Venetoclax in Mantle Cell Lymphoma
NCT03112174Phase 3Completed
- Sponsor
- Pharmacyclics
- Start
- Jun 2017
- Primary completion
- Jun 2024
- Modality
- Small Molecules
- Countries
- 17
01
Overview
Phase 3, randomised, double-blind trial of venetoclax in mantle cell lymphoma (MCL) (4 arms), sponsored by Pharmacyclics. Primary endpoints: Number of Participants With Tumor Lysis Syndrome (TLS) Events at 3 months, Number of Participants With Dose Limiting Toxicities at 3 months and 3 more. Started Jun 2017; status: completed.
02
Drugs
venetoclax
03
Conditions
mantle cell lymphoma (MCL)
Beyond the preview
Go deeper on NCT03112174.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03112174.